Reports broke Monday of a Marburg Virus outbreak in Equatorial Guinea that killed at least nine people.
The World Health Organization announced an ‘urgent meeting’ in response to the outbreak.
World Health Organization Plans ‘Urgent Meeting’ Regarding Marburg Outbreak
WeLoveTrump was among the first to cover Marburg Virus and the possibility of it becoming COVID 2.0.
The Pharma-Industrial Complex, which includes captured government and global health institutions, has laid the groundwork for Marburg Virus to be another Plandemic.
It appears the next steps are being put into motion.
Just before the reports of a Marburg Virus outbreak in Equatorial Guinea, a newly published paper showed “promising results” for an experimental vaccine.
The paper, published in The Lancet, discussed the “first-in-human clinical trial” for an experimental Marburg Virus vaccine.
— Dr. Kat Lindley (@KLVeritas) February 14, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialhttps://t.co/KbRU3tkoKU
— Dr. Li-Meng YAN (@DrLiMengYAN1) February 14, 2023
From the NIH roughly two weeks ago:
A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, could someday be an important tool to respond to Marburg virus outbreaks.
This first-in-human, Phase 1 study tested an experimental MARV vaccine candidate, known as cAd3-Marburg, which was developed at NIAID’s Vaccine Research Center (VRC). This vaccine uses a modified chimpanzee adenovirus called cAd3, which can no longer replicate or infect cells, and displays a glycoprotein found on the surface of MARV to induce immune responses against the virus. The cAd3 vaccine platform demonstrated a good safety profile in prior clinical trials when used in investigational Ebola virus and Sudan virus vaccines developed by the VRC.
MARV, a filovirus in the same family as Ebola virus, causes a rapidly progressive febrile illness that leads to shock and death in a large proportion of infected individuals. Many scientists think that MARV disease outbreaks in humans begin by when the virus makes the jump from its primary animal host, which is likely to be certain chronically infected bats in sub-Saharan Africa. The symptoms of MARV disease are akin to those seen with Ebola virus disease and can include fever, headache, chills, rash, abdominal pain, vomiting, and diarrhea. As the disease progresses, patients may suffer from multiple organ dysfunction, delirium, and significant bleeding from the gastrointestinal tract or other sites that may result in death. No approved vaccines or specific therapies are available for MARV disease, aside from supportive care. While some experimental vaccines have previously been tested, none have proven to be both highly effective and to provide durable protection. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of time would be a crucial part of quelling outbreaks.
In this study, 40 healthy adult volunteers were enrolled at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland. They received a single dose of either a low dose of the vaccine (1×1010 particle units) or a higher dose (1×1011 particle units). For safety, the volunteers were enrolled in a dose-escalation plan. Three participants received the lower dose. Then, when they did not exhibit severe adverse reactions after the first seven days, the trial proceeded to enroll the remaining 17 volunteers. The same procedure was also used for the higher dose group. Volunteers were monitored for adverse reactions to the investigational vaccine and evaluated at regular intervals for 48 weeks to track their immune responses.
The trial’s safety results were encouraging: There were no serious adverse events, and the experimental vaccine was well-tolerated. One participant in the higher dose group developed a fever following vaccination, but it resolved by the following day. In addition, the investigational vaccine appeared to induce strong, long-lasting immunity to the MARV glycoprotein: 95% of participants in the trial exhibited a robust antibody response after vaccination, and 70% maintained that response for more than 48 weeks.
Plans are in place to conduct further trials of the cAd3-Marburg vaccine in Ghana, Kenya, Uganda, and the United States. If additional data supports the promising results seen in the Phase 1 trial, the cAd3-Marburg virus vaccine could someday be used in emergency responses to MARV outbreaks.
Blue Water Vaccines (NASDAQ: BWV) is one biotech company you should remember in the coming months.
The company is reportedly collaborating with AbVacc to jointly develop vaccine candidates targeting Monkeypox and Marburg Virus.
There is an Urgent WHO Marburg Virus Meeting today. $BWV is a company willing to develop a vaccine for this virus. They also filed a 13g today for 18.43% insider ownership. pic.twitter.com/FHKZrO0kH7
— Moon 🌑 (@MoonMarket_) February 14, 2023
$bwv CEO knows what's coming 🚀🚀🚀https://t.co/2A2HQE3diC pic.twitter.com/Aoyb0ScJHd
— imreal forever (@ImrealF) February 14, 2023
$BWV testing pre market highs now in the 1.70s. Watch for buyer volume to come in for a confirmed breakout. Otherwise, expect shorts to try and take this down. Either way we can have a high probability trade here. pic.twitter.com/SJFhyyNZJs
— Mitch Picks (@Mitch___Picks) February 14, 2023
Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc. (“AbVacc”) for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease (“MVD”).
Both candidate vaccines will utilize BWV’s norovirus shell and protrusion (“S&P”) virus-like particle (“VLP”) platform, which allows for the presentation of multiple antigens on the surface of either the S or P particle of a norovirus backbone. BWV previously announced plans to explore a novel monkeypox vaccine candidate using this platform and under this agreement, AbVacc & BWV plan to work collaboratively to optimize the vaccine design and conduct preclinical immunogenicity and efficacy studies. In addition to monkeypox vaccine development, AbVacc will utilize its extensive expertise in MVD to develop a novel vaccine targeting Marburg virus using BWV’s VLP platform.
AbVacc, a recent spin-off of Integrated BioTherapeutics Inc. (“IBT”) developing rationally designed vaccines and monoclonal antibodies, is currently developing a monoclonal antibody for treatment of MVD, IBT-T03, with discovery and preclinical development supported by multiple government grants. In May 2021, IBT was awarded a $16.3M contract from the National Institute of Allergy and Infectious Diseases to support manufacturing and a Phase 1 clinical trial for IBT-T03H. Leveraging this background in MVD, AbVacc & BWV will seek to identify Marburg antigens to be presented within BWV’s VLP platform and optimize a potential vaccine candidate.
More info about Blue Water Vaccines:
Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children’s Hospital Medical Center, St. Jude Children’s Hospital, and The University of Texas Health San Antonio. The Company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children, and prevention of pneumonia in older people at risk for contracting pneumococcal pneumonia, a significant unmet medical need. The advantage of this technology includes a serotype independent mucosal immunity that prevents colonization in the upper respiratory tract as well as systemic immunity that can confer serotype independent against invasive pneumococcal disease. The Company is also developing a Chlamydia vaccine candidate with UT Health San Antonio to prevent infection and reduce the need for antibiotic treatment associated with contracting Chlamydia disease.
BlackRock Fund Advisors and The Vanguard Group, Inc. are listed as two of the top 10 owners of Blue Water Vaccines Inc.
Blue Water Vaccines is also working on a “global flu shot” in attempts to eradicate influenza.
Eradicating Influenza One Step at a Time
Are you tired of locking yourself indoors during flu season? Indeed, all of us are! Thankfully, corporations like Blue Water Vaccines want to finally spare us the trouble of consuming daily vitamins and avoiding the cold like the plague.
Their mission is to create a one-of-a-kind flu shot that won’t require herd immunity but will completely eradicate influenza viruses.
Compared to the current yearly vaccine, which only helps about half of those who get it, recent research and development show that two doses are required to reach immunity. That way, the Blue Water Vaccines flu shot could provide life-long protection against influenza for most patients.
Everything Blue Water Vaccines
Blue Water Vaccines has been working on an influenza cure since 2018.
Soon after Joseph founded the company, CincyTech, a public-private seed-stage investor, showed interest. The organization helped Joseph raise $7 million to invest in creating a vaccine. Since then, the company’s headquarters have been located in Cincinnati, Ohio.
Blue Water Vaccines also works closely with Oxford University. The educational center brings novel technology to the company, which the company has been using for research purposes.
As a reminder, the WHO is discussing vaccine candidates in its ‘urgent meeting’ regarding Marburg Virus.
The #Marburg virus vaccine consortium (MARVAC) is meeting today to discuss the new Marburg virus disease outbreak in #EquatorialGuinea.
They will review available candidate vaccines and their development status.
⏰ 3 p.m. CET
➡️ https://t.co/5ts8NuhkXi pic.twitter.com/WjjFXa0sE2
— World Health Organization (WHO) (@WHO) February 14, 2023
We’ll keep a watchful eye on this story as updates become available.
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!